Description

Eterna Peptides presents premium-grade Tirzepatide (GLP-2 Architecture) lyophilized powder, an elite synthetically structured 39-amino-acid peptide analogue. Functioning as a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist, Tirzepatide is modeled directly after the endogenous human GIP sequence. It features a custom C20 fatty diacid moiety addition that facilitates stable albumin binding to drastically extend its metabolic research half-life. Available in standalone single vials across 5mg, 10mg, 30mg, and 50mg mass configurations, this premium compound serves as an elite investigative tool for tracking synergistic incretin receptor activation, cellular nutrient repartitioning, and metabolic rate adaptation.

### Available Research Configurations
* **Tirzepatide 5mg Vial:** Standardized for early-stage baseline metabolic exposure screens and short-duration cell assay tracking.
* **Tirzepatide 10mg Vial:** Calibrated for mid-tier longitudinal tracking protocols and standard weight management simulation models.
* **Tirzepatide 30mg Vial:** High-capacity presentation engineered for advanced multi-subject protocols and continuous cellular saturation profiles.
* **Tirzepatide 50mg Vial:** Ultra-concentrated mass configuration optimized for intensive dose-response screens and extended experimental timelines.

### Mechanism of Action
Tirzepatide operates via a unique dual-agonist architecture that yields superior metabolic signaling compared to isolated GLP-1 mono-therapies:
* **Synergistic Incretin Receptor Signaling:** Tirzepatide binds with high affinity to both native GIP and GLP-1 receptors. It acts as a full agonist at the GIP receptor network and a biased agonist at the GLP-1 receptor path, driving efficient intracellular cyclic AMP ($cAMP$) accumulation to study optimal pancreatic beta-cell insulin secretion dynamics.
* **Hypothalamic Satiety Alignment:** The structural configuration effectively crosses blood-brain barrier boundaries to interface with pro-opiomelanocortin (POMC) and neuropeptide Y (NPY) neurons in the arcuate nucleus, signaling a down-regulation of food-seeking behaviors and appetite drive pathways.
* **Delayed Gastric Emptying Kinetics:** In metabolic stress models, Tirzepatide is monitored for its capacity to decelerate upper gastrointestinal motility, extending nutrient contact times to study localized satiety feedback loops.
* **Adipose Tissue Browning Regulation:** Via its powerful GIP receptor pathway activity, Tirzepatide is actively investigated for its ability to increase metabolic rate via white adipose tissue repartitioning, tissue-specific insulin sensitivity improvements, and enhanced systemic lipid oxidation ($ \beta\text{-oxidation} $).

### Research Applications
In preclinical and in vitro laboratory models, Tirzepatide (GLP-2) vials are actively utilized to investigate:
* High-velocity lipid mobilization, adipose tissue browning kinetics, and chronic obesity resistance pathways.
* Pancreatic beta-cell protection, glucose-dependent insulin transcription, and type-2 diabetes cellular models.
* Central nervous system satiety pathways, arcuate nucleus neuroplasticity, and behavioral food-seeking motivation curves.
* The comparative efficiency, baseline half-life, and multi-receptor affinity curves of dual GIP/GLP-1 co-agonists.

Our Tirzepatide vials undergo strict laboratory stabilization, vacuum-drying, and high-purity purification guidelines to ensure absolute peptide chain integrity, rapid reconstitution kinetics, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*